eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
SCImago Journal & Country Rank
vol. 28
Poleć ten artykuł:
Artykuł oryginalny

Leczenie statynami i suplementami – bezpieczna i skuteczna terapia zaburzeń lipidowych u dzieci

Małgorzata Grabarczyk
Kinga Pomianowska
Tymoteusz Zaręba-Głód
Agnieszka Zachurzok
Ewa Małecka-Tendera
Paweł Matusik

Medical Student Scientific Society, Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poland
Department of Pediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Department of Pediatrics, Pediatric Obesity and Metabolic Bone Diseases, Chair of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Pediatr Endocrinol Diabetes Metab 2022; 28 (2): 108–113
Data publikacji online: 2022/05/12
Plik artykułu:
- 0163_Statin therapy.pdf  [0.60 MB]
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Lipid disorders, known also as dyslipidemias, are the most common and poorly controlled risk factors leading to cardiovascular complications such as myocardial infarction, stroke and other cardiovascular diseases which stand for 40% of death causes among men and 49% among women in Europe [1]. Among dyslipidemia relevant to the pediatric population we can distinguish atherogenic dyslipidemia (AD) and familial hypercholesterolemia (FH). Atherogenic dyslipidemia (AD) is associated with abnormal nutritional status and includes an elevated triglycerides (TG) concentration as well as high levels of small-dense low-density lipoprotein (sdLDL) and low levels of high-density lipoprotein cholesterol (HDL-C) [2]. Around 1 in 5 children meets the criteria for childhood overweight or obesity, which are often associated with AD. Familial hypercholesterolemia is a genetic disorder inherited in an autosomal dominant pattern [3]. What is more, current data suggest a high prevalence of occurring heterozygous familial hypercholesterolemia (FH). The incidence of heterozygous FH is 1:500 in the general population [4–7]. For an individual who is left untreated, the risk of premature cardiovascular disease is increased by 100-fold [8].
According to published data, there is a significant correlation between elevated LDL cholesterol (LDL-C) levels sustained from childhood and future vascular disease. Children with high LDL-C are likely to become adults with high LDL-C [9–11]. What is more, most of guidelines are based on extrapolated data from the studies on lipid disorders in adults or FH, not from specific investigations [12]. There is a lack of reliable information about LDL-C concentration in children, which can contribute to early atherosclerosis and following cardiovascular diseases. It means, that we still do not know what LDL-C level in children is low enough to avoid future cardiovascular complications [13]. On the other hand, childhood is the optimal period for implementing treatment of dyslipidemia to prevent future cardiovascular complication. However, pharmacological intervention in children with dyslipidemia is still controversial. Especially for statin therapy.
Our study aimed to evaluate the effectiveness and safety of the therapy chosen for children with lipid disorders. Modes of therapy include a non-pharmacological intervention by a low-fat diet, physical activity and dietary supplements, such as red yeast rice, ω-3 fatty acids, plant sterols, plant stanols, as well as statin therapy.

Material and methods

The study group consisted of 37 children with increased LDL-C concentration (13 boys, 24 girls) aged 8.99 ±4.03 years (range: 2.0–17.4 years), managed in the Metabolic Outpatient Clinic. All children underwent 6 months of dietary treatment supported by increased physical activity. Every 3 months patients went to the clinic for check-ups to control fasting lipid profile (total cholesterol [TCh], LDL-C, HDL-C, TG) and periodic height, weight and BMI Z-score control.
After 6 months patients lipid results were reevaluated and due to unsatisfactory treatment results (Table I), our study group was divided into two subgroups: subgroup 1 (G1; n = 24) which continued non-pharmacological treatment (low-fat diet, increased physical activity) supported by dietary supplements (plant stanols, plant sterols, red yeast rice and ω-3 fatty acids); subgroup 2 (G2; n = 13) in which a statin preparation has been added to non-pharmacological treatment. Qualification to a particular mode of treatment and assessment of the effectiveness and safety of therapy chosen for a specified group of children with lipid disorder were based on the guidelines of the Polish Lipid Association (PoLA) from 2016 [12]. In accordance with these guidelines, after 6 months of low-lipid diet children with LDL-C concetration persistent ≥ 190 mg/dl or ≥ 160 mg/dl with other risk factors were classified to G2 treated with non-pharmacological treatment together with statins. Children under the age of 6 years and whose LDL-C concentrations on non-pharmacological treatment were still increased but below 190 mg/dl continued lifestle modification treatment with the inclusion of dietary supplements.
Further treatment was continued for the next ±3 years (range: 0.5–10.7 years). 4 children from G1 were treated with monacolin K (10 mg daily). Statins, which were used in therapy in G2 were: atorvastatin (4 children) and rosuvastatin (9 children). Doses of statins were individualized and varied from 5 to 10 mg daily, depending on age, weight and impact on lipid profile of the child. Analysis included: age, sex, nutritional status (measured via BMI Z-score), fasting lipid profile including TCh, LDL-C, HDL-C and TG measured at several time points (at least 3 times – before treatment, after 6 month of initial treatment and at the last recorded visit). To monitor possible side effects of treatment alanine aminotransferase (AlAT), aspartate transaminase (AspAT) and creatine kinase (CK) were measured every 6 months during the treatment.
Anthropometrical measurements were performed by trained health care professionals (nurses/physicians) using validated equipment. Body weight was measured to the nearest 0.1 kg on a calibrated balance beam scale and body height was measured to the nearest 0.1 cm. All the lipid measurements we performed in fasting state in the same laboratory using enzymatic calorimetric method.
The study was conducted according to the Helsinki declaration and approved by the Ethics Committee of The Medical University of Silesia (KNW/0022/KB1/80/18).
Auxological data and biochemical results were compared using the Statistica 13.3 PL software. All values were expressed as mean±standard deviation. We use Wilcox test to compare the effects of treatment in each group. Differences between the groups were assessed by using U Mann-Whitney test. P-value < 0.05 was considered statistically significant.


Clinical characteristics of the study groups is presented in Table II. The studied groups did not differ in terms of age, BMI Z-score and time of observation. The concentrations of TCh and LDL-C before treatment were significantly higher (p < 0.001) in G2 than in G1 (Table III). Due to the treatment, these statistically significant differences were no longer noticeable at the last visit. In both G1 and G2 concentrations of TCh, LDL-C were reduced significantly, however significantly bigger reduction after the treatment in TCh and LDL-was observed in G2 than in G1 (Table IV). Moreover, in G1 we noticed also significant reduction in TG concentration after treatment (p < 0.05). The BMI Z-score did not change significantly through the treatment in both groups (Fig. 1).
What is more, G1 also showed a significant negative correlation between nutritional status of the child (measured via BMI Z-score) and HDL-C concentration before and after treatment (r = –0.57, p = 0.009; r = –0.52, p = 0.02, respectively). Same relationship was noticed also in G2 after treatment (r = –0.67, p = 0.05). Moreover, in G2, TG concentration before statins implementation correlated with BMI Z-score (r = 0.62, p = 0.04). Neither TCh, nor LDL-C correlated significantly with BMI Z-score.
Based on clinical and biochemical evaluation (AlAT, AspAT, CK), no adverse effects of supplements and statin therapy were observed (Table V). AlAT, AspAT and CK (average CK during treatment 130.0±72.2 IU/l) stayed within the normal range in 100% of patients. Patients did not report any side effects of the statin and monacolin K treatment, including muscle aches.


The study aimed to evaluate the effectiveness and safety of the therapy chosen for 37 children with lipid disturbances enrolled into two subgroups with different treatment modes – G1 treated with non-pharmacological treatment supported by dietary supplements and G2, where non-pharmacological treatment was supported by statins. We found that, in both groups, G1 and G2 concentrations of TCh, LDL-C were reduced significantly, however significantly bigger reduction after the treatment in TCh and LDL-C was observed in G2 than in G1. Moreover based on clinical and biochemical evaluation no adverse effects of supplements and statin therapy were observed.
Dyslipidemia can affect up to 70% of children and tends to maintain from childhood to adulthood, leading to increase cardiovascular disease risk (CVD). However, lipids disturbances are modifiable CVD risk factor and it is extremely important to manage them from the earliest years of life to prevent or to slow down atherogenic process. First line of treatment in childhood dyslipidemia is behavioral treatment which should be implemented regardless of the disorders background [13, 14]. The pharmacological therapy is recommended in children with severe lipid disturbances in whom diet intervention, physical activity and weight management are insufficient in lowering lipids concentration [15]. In most children with secondary dyslipidemia (obesity-related, lifestyle-related) lifestyle changes tend to improve the disorders significantly. In many of these cases the problem is long-term adherence to lifestyle modification. So, as in children with FH, additional treatment is needed also in this group. We decided to include into our study children with lipids disorders regardless of disorder’s cause, and after the 6 months of lifestyle modification in whose with unsatisfactory treatment results, add the pharmacological therapy or supplements lowering lipids concentration. Nowadays statins are recommended as the first choice drugs to treat dyslipidemias. Current studies suggest that for the most beneficial effect statin treatment it should be started in childhood [16]. Delay of the treatment can be a cause of a future cardiovascular diseases developed in young age [12]. Effectiveness and safety of statin usage is well studied in adults, but its ability to reduce intima media thickness was also shown in children with FH. Statins can lower not only LDL-C but also TG levels, as well as raise HDL-C [17]. In our cohort we observed significantly bigger reduction of TCh and LDL-C in children treated with statins than with supplements. But the concentration of TG and HDL-C did not change due to statin treatment. The reduction of TCh and LDL-C in children treated with lifestyle modification and supplements was also significant. In these group of children we decided to use plant stanols, plant sterols, red yeast rice and ω-3 fatty acids [18]. CHILD 2 diet recommends plant stanols and sterol esters in the lipids disorders therapy in children. They were shown to inhibit intestinal cholesterol absorbtion, leading to reduction in LDL-C up to 12%. Additionally mild reduction of TG during their usage is reported [19]. Also ω-3 fatty acids are widely accepted as a supplement used in children. Their exact mechanism of action is not clear but they reduce maily TG level [20]. We can assume that significant reduction in TG concentration after treatment in G1 can be related with both – plant stanols and sterol esters and ω-3 fatty acids supplementation. Red yeast rice supplement, monacolin K, also known as lovastatin, is an inhibitor of liver cholesterol synthesis. It is able to reduce LDL-C on average of 1.02 mmol/l (39.4 mg/dl) compared to placebo [21]. Usually it reduces LDL-C between 15–25% within 6–8 weeks of therapy [22]. Moreover monacolin K, although it has a mechanism of action similar to statins, administration was not associated with increase risk of muscle-related side effects [23]. Unfortunately most of the data about red yeast rice suplements come from observations of adult patients [24]. Data about safety and effeciency in children are very scarse [25]. So we decided to apply monacolin K in only 4 teenagers above the age of 15 years and put those children in G1, as monacolin K is still considered as a dietary supplement and not registered as a medication.
Statin-associated muscle symptoms (SAMS), such as myalgia and muscle weakness, usually mild and completely reversible after treatment discontinuation, can occur in 7–29% of patients and it is associated with CK increase [26]. Patients from our cohort did not report any side effects of the statin and monacolin K treatment, including muscle aches. AlAT, AspAT and CK stayed within the normal range in 100% of patients. Most probably the lack of side effects was related with relatively low dosage of statins and supplement. Also in the short time research of Guardamagna et al. [25] no adverse effects were detected when liver and muscular enzymes (AST, ALT, and CK) were determined in children treated with monacolin K. Our study showed that monacolin K can be a part of successful treatment of dyslipidemia in some cases. Despite no adverse effects reported in our study, further long-term studies are required to predict potential long-term adverse effects of statin and monacolin K as an alternative to statins usage in children [24].


The effectiveness of therapy in children with lipid disorders is highly related to the proper qualification of the patient for the appropriate treatment strategy and must be individualized. Regardless of the decision on pharmacotherapy, the implementation and conduct of appropriate non-pharmacological treatment is of key importance, especially in the case of atherogenic dyslipidemia associated with an abnormal nutritional status. Statin therapy is the most effective in lowering LDL-C. However, therapy with lipids-lowering supplements seems to be safe and effective.


1. Wilkins E, Wilson L, Wickramasinghe K, et al. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels. https://ehnheart.org/images/CVD-statistics-report-August-2017.pdf
2. Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidemia. Indian J Endocrinol Metab 2013; 17: 969–976. doi: 10.4103/2230-8210.122600.
3. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795–1803. doi: 10.1172/JCI18925.
4. Goldberg AC, Hopkins PN, Toth P, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: 133–140. doi: 10.1016/j.jacl.2011.03.452.
5. Civeira F, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55–68. doi: 10.1016/j.atherosclerosis.2003.11.010.
6. Qureshi N, Humphries SE, Seed M, et al. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract 2009; 59: 773–776. doi: 10.3399/bjgp09X472674.
7. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006; 174: 1124–1129. doi: 10.1503/cmaj.051313.
8. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303: 893–896. doi: 10.1136/bmj.303.6807.893.
9. Celermajer DS, Ayer JG. Childhood risk factors for adult cardiovascular disease and primary prevention in childhood. Heart. 2006; 92: 1701–1706. doi: 10.1136/hrt.2005.081760.
10. Pletcher MJ, Bibbins-Domingo K, Liu K, et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med 2010; 153: 137–146. doi: 10.7326/0003-4819-153-3-201008030-00004.
11. Mimoun E, Aggoun Y, Pousset M, et al. Association of arterial stiffness and endothelial dysfunction with metabolic syndrome in obese children. J Pediatr 2008; 153: 65–70. doi: 10.5603/KP.2013.0276.
12. Banach M, Jankowski P, Jóźwiak J, et al. Wytyczne PTL/KLRwP/PTK postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016 in Lekarz POZ 2016; 4: 251–301.
13. Myśliwiec M, Walczak M, Małecka-Tendera E, et al. Lipid Expert Forum. Postępowanie w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych [Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum]. Kardiol Pol 2013; 71: 1099–1105.
14. Kwiterovich POJ. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008; 93: 4200–4209. doi: 10.1210/jc.2008-1270.
15. Fiorentino R, Chiarelli F. Treatment of Dyslipidaemia in Children. Biomedicines 2021; 9: 1078. doi: 10.3390/biomedicines9091078.
16. Cybulska B, Kłosiewicz-Latoszek L. Komentarz do artykułu „Ocena skuteczności i bezpieczeństwa stosowania statyn u dzieci chorych na rodzinną hipercholesterolemię”. Medycyna Praktyczna 2016. Available at: http://www.mp.pl/artykuly/26863 (30.06.2016).
17. Newman CB, Preiss D, Tobert JA, et al. American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019; 39: e38–e81. doi: 10.1161/ATV.0000000000000073.
18. Cicero AFG, Fogacci F, Stoian AP, et al. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Curr Atheroscler Rep 2021; 23: 57. doi: 10.1007/s11883-021-00955-y.
19. Gylling H, Plat J, Turley S, et al. European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346–360. doi: 10.1016/j.atherosclerosis.2013.11.043.
20. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation 2019; 140: e673–e691. doi: 10.1161/CIR.0000000000000709.
21. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 2004; 35: 1101–1112. doi: 10.1016/j.jpba.2004.04.004.
22. Cicero AFG, Fogacci F, Zambon A. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. J Am Coll Cardiol 2021; 77: 620–628. doi: 10.1016/j.jacc.2020.11.056.
23. Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2019; 143: 1–16. doi: 10.1016/j.phrs.2019.02.028.
24. Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014; 9: e98611. doi: 10.1371/journal.pone.0098611.
25. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract andpolicosanols. Nutr Metab Cardiovasc Dis 2017; 21: 424–429. doi: 10.1016/j.numecd.2009.10.015.
26. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012–1022. doi:10.1093/eurheartj/ehv043.

facebook linkedin twitter
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.